NCT05074472View on ClinicalTrials.gov

A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

January 14, 2022

Primary Completion Date

August 30, 2023

Study Completion Date

September 30, 2023

Conditions
Solid Tumor, AdultPancreatic Ductal; AdenocarcinomaOvarian Serous AdenocarcinomaBiliary Cancer MetastaticOvarian Serous Cystadenocarcinoma
Interventions
DRUG

ZB131

ZB131 will be administered once weekly by intravenous infusion with the weight at baseline used for mg/kg dose calculations.

Trial Locations (9)

22031

NEXT Onoology, Fairfax

22908

University of Virginia, Charlottesville

32224

Mayo Clinic Jacksonville, Jacksonville

37203

Sarah Cannon Research Institute, Nashville

55905

Mayo Clinic - Rochester, Rochester

77030

MD Anderson Cancer Center, Houston

78229

NEXT Oncology, San Antonio

78758

NEXT Oncology, Austin

85054

Mayo Clinic - Phoenix, Phoenix

All Listed Sponsors
lead

ZielBio, Inc.

INDUSTRY